NY-ADACORE
13.6.2024 11:23:28 CEST | Business Wire | Press release
AdaCore https://www.adacore.com/ is thrilled to be part of the Safety-Critical Rust Consortium alongside The Rust Foundation, Arm, Ferrous Systems, OxidOS, Synopsys, HighTec EDV-Systeme GmbH, TrustInSoft, Veecle, and Woven by Toyota. The primary objective of this group will be to support the responsible use of the Rust programming language in safety-critical software — systems whose failure can impact human life or cause severe environmental or property harm.
Safety-Critical Rust Consortium Membership is open to Rust Foundation member organizations and other invitees, such as industry, academic, and legal experts.
Work under the consortium will begin with the creation of a public charter and goals, and meeting minutes will be published on an ongoing basis. The Safety-Critical Rust Consortium will liaise with the Rust Project through Rust Foundation Project Directors and members of Rust Project teams. The Consortium’s scope, which will be fully delineated in the charter, may include the development of guidelines, linters, libraries, static analysis tools, formal methods, and language subsets to meet industrial and legal requirements. The Consortium’s deliverables will be developed and licensed in a manner compatible with other Rust Project endeavors.
The group may further shepherd Rust Foundation-funded implementation work, including grants to existing academic teams or FOSS projects. Any Rust Foundation-funded work will be submitted upstream, licensed as FOSS, and any specifications will be freely available. The group will further attempt to coordinate with and expand on existing safety-critical projects and standards including SAE JA1020.
Programming-language safety refers to a language’s ability to prevent errors or undefined behaviors at compile time or runtime. On the other hand, "safety-critical" refers to a system’s ability to operate without causing accidents or catastrophic failures that will result in harm to people, property or the environment. So, while safety-critical systems rely on languages that emphasize safety and security, such as Rust, programming tools are only one component of the overall strategy.
Tony Aiello is the Product Manager at AdaCore,
“At AdaCore, we focus on industries where safety, security, and reliability are paramount including automotive, aviation, and space. AdaCore has decades of experience serving these industries with Ada, SPARK, and C++. Participating in the Safety-Critical Rust Consortium enables us to leverage our expertise to help the Rust community best position itself to serve the safety-critical community’s needs.”
About AdaCore
Everything we do at AdaCore is centered around helping developers build safe, secure and reliable software. With over 30 years of experience working with the most respected companies in industries such as aerospace, defense and railways, we build tools and provide services that ease the complex and often difficult process of developing high-integrity software. As the need for truly secure and reliable applications expands into industries such as automotive, medical, energy, and IoT, we’re excited to bring our time-tested technologies, expertise and services to help a whole new generation of developers.
About The Rust Foundation
The Rust Foundation is an independent nonprofit dedicated to the safety, security, sustainability, and health of the Rust Programming language and the people who use it. Through close partnerships with organizations passionate about Rust and the growing Rust Project and community, the Rust Foundation is helping forge a better open-source future with Rust.
Visit the Rust Foundation website to learn more. Follow the Rust Foundation on X (formerly known as Twitter) and on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240613424332/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
